Mitsubishi Tanabe Pharma: Pipeline, Products, Performance, Potential

Date: April 22, 2009
Pages: 100
US$ 1,040.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Mitsubishi Tanabe Pharma: Pipeline, Products, Performance, Potential
On 1st October 2007, Mitsubishi Tanabe Pharma Corporation was created through the merger of Tanabe Seiyaku and Mitsubishi Pharma. Tanabe is the surviving company, with each share of Mitsubishi converted into 0.69 share of Tanabe's common stock. The new company is a consolidated subsidiary of Mitsubishi Chemical Holdings, which holds the majority share.

With its headquarters in Tokyo, Japan and a network of regional headquarters in the US, Europe and Asia, Mitsubishi Tanabe Pharma aims to establish its position as a global, research-driven pharmaceutical company. The company manufactures and sells ethical and generic pharmaceuticals, as well as fine chemicals and active pharmaceutical ingredients or intermediates. Mitsubishi Tanabe Pharma’s initial focus is on the development and marketing of products in the following therapeutic areas: Cardiovascular and Respiratory; Neurology; Immunology and Inflammation; and Gastrointestinal and Metabolism.

Market conditions in Japan are becoming increasingly fierce due to governmental drug price revisions and incoming competition from non-domestic major pharmaceutical companies. In the last two fiscal years, there have been four mergers between Japan’s leading pharma businesses, with the creation of Mitsubishi Tanabe Pharm being the latest. More recently, Kyowa Hakko and Kirin Brewery merged on 1st October 2008.

Superficially, Mitsubishi Pharma and Tanabe would seem to compliment each other quite well, with both historically marketing products in similar therapeutic areas and both bringing unique qualities to create a well equipped merged company. Mitsubishi Pharma’s product portfolio was the most dated, however, the company brings to the merger considerable resources and infrastructure in biotechnology, mainly through its Benesis Corporation. Tanabe has several lucrative licensing agreements in place and thus the merged company is expected to continue to benefit from these. Tanabe’s arrangement with Johnson & Johnson is key to Mitsubishi Tanabe’s long-term growth as it includes licences for infliximab and golimumab, two anti-TNF antibodies indicated to treat a range of inflammatory and autoimmune indications. Infliximab has been launched in Japan and became Mitsubishi Tanabe Pharma’s top-selling product in fiscal 2008. Golimumab only entered Phase II/III development in Japan in July 2008, however, its similar profile to infliximab suggests development should be successful, and the company will hope it can replicate the sales of infliximab.

Both parent companies had previously reported declines in revenue and pharmaceutical sales, therefore, this merger was vital. Our forecasts suggest that Mitsubishi Tanabe can expect sustained growth within the medium-term, confirming the benefits of the merger strategy. However, with four other large, merged companies competing domestically, competition is fierce and is expected to impact the merged company in the long-term as much as it did the parent companies in recent history.

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.


Key product analysis and forecasting
Cardiovascular & Respiratory
  Anplag (sarpogrelate)
  Herbesser (diltiazem)
  Tanatril (imidapril)
  Ceredist (taltireline)
  Radicut (edavarone)
Immunology & Inflammation
  Remicade (infliximab)
  Talion (bepotastine besilate)
Gastrointestinal & Metabolism
  Urso (ursodeoxycholic acid)


A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Subsidiaries and joint ventures
Skip to top

Ask Your Question

Mitsubishi Tanabe Pharma: Pipeline, Products, Performance, Potential
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: